Stock comparison
Haemonetics
Innoviva
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
INVA
Innoviva
Market cap
$1.66B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | INVA | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 51C | HAE |
| Benjamin Graham | 85A | 50C | HAE |
| Philip Fisher | 60C | 44D | HAE |
| Peter Lynch | 54C | 16F | HAE |
| Joel Greenblatt | 31F | 32F | INVA |
| Charlie Munger | 54D | 47D | HAE |
| Terry Smith | 55D | 46D | HAE |
Side-by-side metrics
| Metric | HAE | INVA |
|---|---|---|
| Market cap | $2.98B | $1.66B |
| P/E (TTM) | 24.8x | 3.3x |
| EV/EBIT | 14.1x | 8.6x |
| ROIC (TTM) | 8.37% | 2.93% |
| Gross margin | 55.74% | 76.2% |
| Net margin | 7.29% | 118.91% |
| Revenue CAGR 5y | 7.65% | 2.06% |
| EPS CAGR 5y | 24.62% | 5.54% |
| Debt / Equity | 1.5x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs 5.54%+77%
- Revenue CAGR 5y7.65%vs 2.06%+73%
- ROIC (TTM)8.37%vs 2.93%+65%
- Market cap$2.98Bvs $1.66B+44%
INVA leads on
- Net margin118.91%vs 7.29%+94%
- P/E (TTM)3.3xvs 24.8x+87%
- Debt / Equity0.2xvs 1.5x+84%
- EV/EBIT8.6xvs 14.1x+39%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.